Monte Rosa Therapeutics (GLUE) Share-based Compensation (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Share-based Compensation of $49.4 million for Q1 2026, up 832.43% year-over-year from $5.3 million in Q1 2025, and up 1046.44% quarter-over-quarter from $4.3 million in Q4 2025.
Monte Rosa Therapeutics (GLUE) Share-based Compensation (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $49.4 million for Q1 2026.
- In Q1 2026, Share-based Compensation rose 832.43% year-over-year to $49.4 million; the TTM figure through Mar 2026 stood at $49.4 million (up 166.29% YoY), while the FY2025 annual figure was $24.2 million, up 4.31% from the prior year.
- Share-based Compensation for Q1 2026 stood at $49.4 million, up from $4.3 million in the prior quarter.
- The five-year high for Share-based Compensation was $49.4 million in Q1 2026, with the low at $100000.0 in Q2 2023.
- The 5-year median for Share-based Compensation is $4.4 million (2025), against an average of $9.9 million.
- Peak annual rise in Share-based Compensation reached 16450.0% in 2023, while the deepest fall reached 99.72% in 2023.
- Monte Rosa Therapeutics' Share-based Compensation stood at $3.3 million in 2022, then climbed by 22.49% to $4.1 million in 2023, then advanced by 9.7% to $4.5 million in 2024, then retreated by 3.58% to $4.3 million in 2025, then surged by 1046.44% to $49.4 million in 2026.
- Business Quant data shows GLUE's Share-based Compensation at $49.4 million in Q1 2026, $4.3 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Monte Rosa Therapeutics | 1.32 Bn | 688.11 Mn | - | 5.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.97 Mn |
| Jun 30, 2026 | 5.97 Mn |
| Mar 31, 2026 | 49.40 Mn |
| Mar 31, 2026 | 49.40 Mn |
| Dec 31, 2025 | 4.31 Mn |
| Dec 31, 2025 | 4.31 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Sep 30, 2025 | 4.36 Mn |
| Jun 30, 2025 | 4.89 Mn |
| Jun 30, 2025 | 4.89 Mn |
| Mar 31, 2025 | 5.30 Mn |
| Mar 31, 2025 | 5.30 Mn |
| Dec 31, 2024 | 4.47 Mn |
| Dec 31, 2024 | 4.47 Mn |
| Sep 30, 2024 | 4.28 Mn |
| Sep 30, 2024 | 4.28 Mn |
| Jun 30, 2024 | 4.50 Mn |
| Jun 30, 2024 | 4.50 Mn |
| Mar 31, 2024 | 4.87 Mn |
| Mar 31, 2024 | 4.87 Mn |